2023 Form 5500 filing — Sebela Pharmaceuticals Inc. 401(K) Plan
Plain-English filing summary
According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20240801091147NAL0049154626001) for Sebela Pharmaceuticals Inc. 401(K) Plan, reported by Braintree Laboratories, Inc. under EIN 04-2769947 and plan number 001. It reports 474 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).
Form 5500 2 · 2023
Filing snapshot
Net assets (EOY)$67.8MReported net assets$67,842,645
Participants474
Provider compensation$57K2 Schedule C row(s)$57,013
Schedules filedSchedule H, Schedule CLoaded schedules
- EFAST2 acknowledgement
- 20240801091147NAL0049154626001
- Plan sponsor
- Braintree Laboratories, Inc.
- EIN
- 04-2769947
- Plan number
- 001
- Location
- Braintree, MA
- Received date
- not reported in the loaded dataset
Schedule H · 2023
Reported financial snapshot
Reported figures as filed, in whole dollars. Only fields the filing reports are shown.
Reported balance (end of year)$67.8M total assets
Net assets$67.8MLiabilities$0
Full reported line items
- Total assets (EOY)
- $67,842,645
- Total liabilities (EOY)
- $0
- Net assets (EOY)
- $67,842,645
- Employer contributions
- $1,226,795
- Participant contributions
- $3,427,012
- Total income / additions
- $16,769,648
- Benefits paid
- $2,709,568
- Administrative expenses
- $57,014
- Total expenses
- $2,766,582
- Net increase / (decrease)
- $14,003,066
Reported service provider compensation (Schedule C)
| Provider | Service | Direct comp. | Indirect comp. |
|---|---|---|---|
| John Hancock | RETAINED BY EMPLOYER | $42,212 | $0 |
| Lincoln National Corporation | SERVICE PROVIDER | $14,801 | $0 |